IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Paten	t Application of		
MATSUDA		Atty. Ref.:	159-115
Serial No.	10/567,728	Group:	1632
Filed:	January 31, 2006	Examiner:	BERTOGLIO, Valarie E
For: THF	REE-DIMENSIONAL TISSUE	STRUCTURE	
	* * * *	* * * * * *	* *
P.O. Box 1	oner for Patents 450 , VA 22313-1450	August	29, 2011
Sir:	INFORMATION DI	ISCLOSURE STATEMI	<u>ENT</u>
<u> </u>	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C		
	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C		
2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00		
3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00		

Information Disclosure Statement August 29, 2011

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

	_	-			
	4.	ider eac	st of documents on Form PTO-1449 together with copies of each ntified document and a translation or a concise explanation of the non-English language document (such as a Search Report) is closed herewith.		
This	paper	is sub	omitted in accordance with:		
	5.	37 (CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]		
\boxtimes	6.	37 (and	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]		
	\boxtimes	a)	The required Statement made in item 8 below; or		
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.		
7.		37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and			
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and		
		b)	The required Statement is stated in item 8 below.		
⊠ 8.		Statement under 37 CFR 1.97(e)			
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or		
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		

MATSUDA Appln. No. 10/567,728 Information Disclosure Statement August 29, 2011

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

August 29, 2011 Sheet 1 of ATTY. DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE **CITATION** 10/567,728 159-115 **APPLICANT MATSUDA** (Use several sheets if necessary) FILING DATE GROUP January 31, 2006 1632 **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE INITIAL DOCUMENT NUMBER NAME CLASS **SUBCLASS** IF APPROPRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Menasche et al, "Myoblast transplantation for heart failure", THE LANCET, Vol. 357, January 27, 2001, pages 279-280 Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.